Relaxation Ofcat Trachea by 13-Adrenoceptor Agonists

Total Page:16

File Type:pdf, Size:1020Kb

Relaxation Ofcat Trachea by 13-Adrenoceptor Agonists Br. J. Pharmac. (1983), 78,417-424 Relaxation of cat trachea by 13-adrenoceptor agonists can be mediated by both f3I- and 132-adrenoceptors and potentiated by inhibitors of extraneuronal uptake Stella R. O'Donnell & Janet C. Wanstall Pharmacology Section, Department of Physiology and Pharmacology, University of Queensland, St Lucia, Brisbane, Qld. 4067, Australia 1 Responses (relaxation) to the P-adrenoceptor agonists, isoprenaline, fenoterol or noradrenaline, were obtained on cat tracheal preparations contracted with a submaximal concentration of carbachol (0.5 JAM). 2 The relative potencies of isoprenaline: fenoterol: noradrenaline were 100:8.1:10.7. From this, it was concluded that responses were mediated predominantly by 131-adrenoceptors but that a minor population of P2-adrenoceptors might also be involved. 3 Schild plots for the selective antagonists atenolol (Pi1-selective) or ICI 118,551 (32-selective) were in different locations, i.e. were separated, depending on whether the antagonist was antagoniz- ing noradrenaline or fenoterol. This supported the conclusion that 12- as well as Pl-adrenoceptors were involved in mediating the response. In this respect, cat trachea resembles cat atria (rate responses). 4 In the presence of atenolol the concentration-response curves to fenoterol became biphasic. This was interpreted as indicating that the P2-adrenoceptors were too few in number to elicit a maximum tissue response. 5 Responses to isoprenaline of cat trachea were potentiated by the extraneuronal uptake inhibitor drugs, corticosterone and metanephrine. This indicated that extraneuronal uptake could modulate P-adrenoceptor-mediated responses (relaxation) of cat trachea. 6 Cat trachea resembles guinea-pig trachea in that (i) the P-adrenoceptor population mediating relaxation is mixed (PI + P2) and (ii) responses to isoprenaline are modulated by its extraneuronal uptake. However, cat trachea differs from guinea-pig trachea in that the predominant 1- adrenoceptor sub-type is Pi not P2- Introduction In cat trachea, the P-adrenoceptors mediating relaxa- interest to determine whether the influence of ex- tion were classified by Lulich, Mitchell & Sparrow traneuronal uptake on ,B-adrenoceptor-mediated (1976) as P1-adrenoceptors. Thus they appeared to tracheal relaxation was also different in the two be different from the P-adrenoceptors mediating re- species. This question was relevant to the hypothesis sponses in guinea-pig trachea, which were originally that extraneuronal uptake may be more closely as- said to be P2-adrenoceptors (Farmer & Levy, 1970). sociated with P2-adrenoceptors than pl- More recently, it has been possible to demonstrate adrenoceptors (Bryan, Cole, O'Donnell & Wanstall, that PI as well as P2-adrenoceptors can mediate relax- 1981). An extraneuronal uptake of catecholamines ation of guinea-pig trachea (Furchgott, 1976; has been demonstrated in the trachealis smooth mus- O'Donnell & Wanstall, 1979a). Therefore it was of cle cells from both species, using a fluorescence his- interest to determine whether tracheal relaxation in tochemical technique (Anning, Bryan & O'Donnell, cat could also be mediated by both sub-types of 1978) and responses to isoprenaline on guinea-pig P-adrenoceptor. trachea are known to be potentiated when this up- Because the P-adrenoceptor sub-type predomin- take is inhibited by extraneuronal uptake inhibitor antly responsible for tracheal relaxation was appar- drugs (O'Donnell & Wanstall, 1976). Experiments ently different in guinea-pig and cat, it was also of have now been carried out to determine whether 0007-1188/83/020417-08 $01.00 'P) The Macmillan Press Ltd 1983 418 STELLA R. O'DONNELL & JANET C. WANSTALL potentiation of isoprenaline by extraneuronal uptake used (see Results), values of concentration-ratio inhibitor drugs can be demonstrated on cat trachea. (CR) were calculated from the EC50 in the presence A preliminary report of some of these data formed of the antagonist divided by the EC50 in the absence part of a communication to the British Pharmacologi- of antagonist (control). It was not necessary to cor- cal Society (Cole, O'Donnell & Wanstall, 1982). rect these CR values since, in a separate series of experiments, it was shown that there was no signific- ant change in sensitivity of the preparations with time Methods and/or pre-exposure to the agonists. Plots of log Cat trachealpreparations (CR-1) vs. log molar concentration of antagonist (log [B]) were obtained according to the method of Cats of either sex, weighing 1.5 to 3.5 kg, were pre- Arunlakshana & Schild (1959). A linear least treated with reserpine (0.1 mg/kg i.p. 18 h previous- squares regression analysis (Snedecor & Cochran, ly). They were anaesthetized with ether and then 1967) was used to obtain the line of best fit through exsanguinated. The trachea was removed and single the combined data points from a number of cats, and ring preparations (up to 4 preparations from each this line is referred to as a Schild plot. None of the cat) were set up in Krebs solution at 37°C and gassed Schild plots had slopes which differed significantly with 95% 02 and 5% CO2. In some experiments the from 1.0 (Table 2). Thus pA2 values could be calcu- whole tracheal ring was mounted, at a resting tension lated for each concentration of antagonist used from of 1.5 g, around two horizontal stainless steel pins the equation pA2 = log (CR-1) - log [B] and a mean (one fixed and one linked to a Statham Universal pA2 value obtained for each cat. For each agonist- transducer, UC3 + UL5) and changes in isometric antagonist combination a mean pA2 value ± s.e. was tension recorded. In other experiments, most of the then calculated from a number of animals. cartilage was removed from the ring and the remain- ing smooth muscle preparation was set up, at a ten- Effects ofextraneuronal uptake inhibitors on sion of 300 mg, so that changes in length could be isoprenaline-induced relaxation ofcat trachea recorded isotonically using a modified Statham lOB strain gauge. No quantitative differences were ob- a-Adrenoceptors and neuronal uptake were blocked served between these two types of preparation. Prep- with phentolamine (10 Mm) and cocaine (10jM) re- arations taken from the region of the trachea nearest spectively. Concentration-response curves to isop- to the larynx are referred to as from the cervical renaline were obtained in the absence and presence trachea and those taken just before the trachea bifur- of metanephrine (50 Mm) or of increasing concentra- cated into the bronchi are referred to as from thoracic tions (1, 10 and 50 Mm) of corticosterone. The in- trachea. hibitors were in contact with the tissue for 30 min Preparations were contracted with a submaximal before, and also during, the isoprenaline concentration (0.5 pM) of carbachol. Cumulative concentration-response curve. The corticosterone concentration-response (relaxation) curves were ob- stock solution was made up in absolute ethanol. tained to P-adrenoceptor agonist drugs and EC50 Therefore in the cortiscosterone experiments, a con- values (molar concentration of agonist producing stant concentration of ethanol (17.2 mM) was main- 50% maximum response) interpolated. The potency tained in the organ bath throughout the experiment of the agonist drugs was expressed as the negative log by adding, when necessary, an appropriate amount of EC50. absolute ethanol to the Krebs solution in the organ bath before obtaining an isoprenaline concentration- Schildplotsforfi-adrenoceptorantagonists on cat response curve. Potentiation of isoprenaline, i.e. shift trachea of the log concentration-response curve to a lower concentration range, was calculated from [neg log a-Adrenoceptors, neuronal uptake and extraneuron- EC50 (inhibitor present) - neg log EC50 (control)]. In al uptake were blocked with phentolamine (10 Mm), 4 of the 10 experiments with metanephrine the cocaine (10 AM) and metanephrine (50 AM) respec- potentiation of isoprenaline was corrected to allow tively (in contact with the tissue for 30 min before and for antagonism of isoprenaline due to the weak P- then throughout the experiments). Concentration- adrenoceptor antagonist action of metanephrine response curves to either fenoterol (32-selective (Kenakin, 1980). In order to do this, concentration- agonist) or noradrenaline (pl-selective agonist) were response curves were obtained for both fenoterol and obtained in the absence and presence of increasing isoprenaline (in random order), in the absence and concentrations of a ,-adrenoceptor antagonist. The presence of 50 Mm metanephrine. Fenoterol is not a contact time for the antagonist drugs was 60 min. substrate for extraneuronal uptake and metane- Except in the experiments with atenolol using phrine antagonized responses to fenoterol, i.e. fenoterol as agonist, when a different approach was shifted the fenoterol concentration-response curves P-ADRENOCEPTORS AND EXTRANEURONAL UPTAKE IN TRACHEA 419 to a higher concentration range. Thus corrected val- solutions were made in Krebs solution and kept on ues for the potentiation of isoprenaline by metanep- ice during the course of the experiment. hrine, due to inhibition of extraneuronal uptake, The composition of the Krebs solution was (mM): were obtained by adding the value for the antagonism NaCl 114, KCl 4.7, CaCl2 2.5, KH2PO4 1.2, MgSO4 of fenoterol (in log units) to the value for the potenti- 1.2, NaHCO3 25, glucose 11.7, ascorbic acid 1.1. ation of isoprenaline (in log units). Statistical analyses Cat right atrial
Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al
    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Pharmacodynamic Evaluation of Β-Blockade Associated with Atenolol
    Pharmacodynamic HYDOXDWLRQRIȕ-blockade associated with atenolol in healthy dogs Mari Waterman Thesis submitted to the faculty of the Virginia Polytechnic Institute and State University in partial fulfillment of the requirements for the degree of Master of Science In Biomedical and Veterinary Sciences Jonathan A. Abbott, Chair Andrea C. Eriksson Jeffrey R. Wilcke July 30, 2018 Blacksburg, VA .H\ZRUGVDWHQROROȕ-blockade, isoproterenol, dog, pharmacodynamic Copyright 2018 Mari Waterman Pharmacodynamic HYDOXDWLRQRIȕ-blockade associated with atenolol in healthy dogs Mari Waterman ABSTRACT Objective: Dosing intervals of 12 and 24 hours for atenolol have been recommended, but an evidentiary basis is lacking. To test the hypothesis that repeated, once-daily oral administration of atenolol attenuates the heart rate response to isoproterenol for 24 hours, we performed a double-blind, randomized, placebo-controlled cross-over experiment. Animals: Twenty healthy dogs Procedures: Dogs were randomly assigned to receive either placebo (P) and then atenolol (A), [1 mg/kg PO q24h] or vice versa. Treatment periods were 5-7 days; time between periods was 7 days. Heart rates (bpm) at rest (HRr DQG GXULQJ FRQVWDQW UDWH > ȝJNJPLQ@ LQIXVLRQ RI isoproterenol (HRi) were electrocardiographically obtained 0, 0.25, 3, 6, 12, 18, and 24 hours after final administration of drug or placebo. A mixed model ANOVA was used to evaluate the effects of treatment (Tr), time after drug or placebo administration (t), interaction of treatment and time (Tr*t) as well as period and sequence on HRr and HRi. Results: Sequence or period effects were not detected. There was a significant effect of Tr (p <0.0001) and Tr*t (p <0.0001) on HRi.
    [Show full text]
  • Ovid MEDLINE(R)
    Supplementary material BMJ Open Ovid MEDLINE(R) and Epub Ahead of Print, In-Process & Other Non-Indexed Citations and Daily <1946 to September 16, 2019> # Searches Results 1 exp Hypertension/ 247434 2 hypertens*.tw,kf. 420857 3 ((high* or elevat* or greater* or control*) adj4 (blood or systolic or diastolic) adj4 68657 pressure*).tw,kf. 4 1 or 2 or 3 501365 5 Sex Characteristics/ 52287 6 Sex/ 7632 7 Sex ratio/ 9049 8 Sex Factors/ 254781 9 ((sex* or gender* or man or men or male* or woman or women or female*) adj3 336361 (difference* or different or characteristic* or ratio* or factor* or imbalanc* or issue* or specific* or disparit* or dependen* or dimorphism* or gap or gaps or influenc* or discrepan* or distribut* or composition*)).tw,kf. 10 or/5-9 559186 11 4 and 10 24653 12 exp Antihypertensive Agents/ 254343 13 (antihypertensiv* or anti-hypertensiv* or ((anti?hyperten* or anti-hyperten*) adj5 52111 (therap* or treat* or effective*))).tw,kf. 14 Calcium Channel Blockers/ 36287 15 (calcium adj2 (channel* or exogenous*) adj2 (block* or inhibitor* or 20534 antagonist*)).tw,kf. 16 (agatoxin or amlodipine or anipamil or aranidipine or atagabalin or azelnidipine or 86627 azidodiltiazem or azidopamil or azidopine or belfosdil or benidipine or bepridil or brinazarone or calciseptine or caroverine or cilnidipine or clentiazem or clevidipine or columbianadin or conotoxin or cronidipine or darodipine or deacetyl n nordiltiazem or deacetyl n o dinordiltiazem or deacetyl o nordiltiazem or deacetyldiltiazem or dealkylnorverapamil or dealkylverapamil
    [Show full text]
  • Novel Method of Administering Β-Blockers and Novel Dosage Forms Containing Same Anwar A
    University of Kentucky UKnowledge Pharmaceutical Sciences Faculty Patents Pharmaceutical Sciences 1-31-1984 Novel Method of Administering β-Blockers and Novel Dosage Forms Containing Same Anwar A. Hussain University of Kentucky Right click to open a feedback form in a new tab to let us know how this document benefits oy u. Follow this and additional works at: https://uknowledge.uky.edu/ps_patents Part of the Pharmacy and Pharmaceutical Sciences Commons Recommended Citation Hussain, Anwar A., "Novel Method of Administering β-Blockers and Novel Dosage Forms Containing Same" (1984). Pharmaceutical Sciences Faculty Patents. 124. https://uknowledge.uky.edu/ps_patents/124 This Patent is brought to you for free and open access by the Pharmaceutical Sciences at UKnowledge. It has been accepted for inclusion in Pharmaceutical Sciences Faculty Patents by an authorized administrator of UKnowledge. For more information, please contact [email protected]. Unlted States Patent [191 [11] 4,428,883 Hussain [45] Jan. 31, 1984 [54] NOVEL METHOD OF ADMINISTERING 4,012,444 3/l977 Lunts ................................. .. 424/ 324 B-BLOCKERSF0 RMS Co NTA' AND, INING NOVEL SAME DOSAGE ' 4,250,163, , 1.1’;2/l981 llieoll’loldNagaioe a ......................................... ---- -~.. .. 424/14 [7 5 ] I nventor : An war A . Hussam,° Lexington' , Ky . FOREIGN PATENT DOCUMENTS [73] Assignee: The University of Kentucky Research . Foundation’ Lexington, Ky. 979389 1/ 1965 United Klngdom . I [21] APPL Nod 241,413 OTHER PUBLICATIONS . Stern, Arzmit. Forsch, vol. 24, 1974, pp. 70-71. [22] Flled‘ Mm‘- 6’ 1981 Black, Brit. J. PharmacoL, (1965) 25, pp. 577-591. [51] Int. Cl.3 ................... .. A61K 27/00; A61K 31/15; Prima'y Examiner_stanley L Friedman A61K 31/40; A61K 31/47; A61K 31/135; Attorney, Agent, or Firm-Burns, Doane, Swecker & A61K 31/165; A61K 31/435; A61K 31/475; Mathis A61K 47/00; C07C 143/90; CllD 1/28; C09F - 5 /()() [57] ABSTRACT [52] US.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Drugs for Primary Prevention of Atherosclerotic Cardiovascular Disease: an Overview of Systematic Reviews
    Supplementary Online Content Karmali KN, Lloyd-Jones DM, Berendsen MA, et al. Drugs for primary prevention of atherosclerotic cardiovascular disease: an overview of systematic reviews. JAMA Cardiol. Published online April 27, 2016. doi:10.1001/jamacardio.2016.0218. eAppendix 1. Search Documentation Details eAppendix 2. Background, Methods, and Results of Systematic Review of Combination Drug Therapy to Evaluate for Potential Interaction of Effects eAppendix 3. PRISMA Flow Charts for Each Drug Class and Detailed Systematic Review Characteristics and Summary of Included Systematic Reviews and Meta-analyses eAppendix 4. List of Excluded Studies and Reasons for Exclusion This supplementary material has been provided by the authors to give readers additional information about their work. © 2016 American Medical Association. All rights reserved. 1 Downloaded From: https://jamanetwork.com/ on 09/28/2021 eAppendix 1. Search Documentation Details. Database Organizing body Purpose Pros Cons Cochrane Cochrane Library in Database of all available -Curated by the Cochrane -Content is limited to Database of the United Kingdom systematic reviews and Collaboration reviews completed Systematic (UK) protocols published by by the Cochrane Reviews the Cochrane -Only systematic reviews Collaboration Collaboration and systematic review protocols Database of National Health Collection of structured -Curated by Centre for -Only provides Abstracts of Services (NHS) abstracts and Reviews and Dissemination structured abstracts Reviews of Centre for Reviews bibliographic
    [Show full text]
  • Self-Measured Compared to Office
    Systematic Review for the 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Supplemental Tables and Figures Part 1: Self-Measured Compared to Office-Based Measurement of Blood Pressure in the Management of Adults With Hypertension Table 1.1 Electronic search terms used for the current meta-analysis (Part 1 – Self-Measured Compared to Office-Based Measurement of Blood Pressure in the Management of Adults With Hypertension). PubMed Search (Blood Pressure Monitoring, Ambulatory [mesh] OR self care [mesh] OR telemedicine [mesh] OR patient participation [tiab] OR ambulatory [tiab] OR kiosk [tiab] OR kiosks [tiab] OR self-monitor* [tiab] OR self-measure* [tiab] OR self-care* [tiab] OR self-report* [tiab] OR telemonitor* [tiab] OR tele-monitor* [tiab] OR home monitor* [tiab] OR telehealth [tiab] OR tele-health [tiab] OR telemonitor* [tiab] OR tele-monitor* [tiab] OR telemedicine [tiab] OR patient-directed [tiab] OR Blood pressure monitoring “patient directed” [tiab] OR HMBP [tiab] OR SMBP [tiab] OR home [tiab] OR white coat [tiab] OR concept + Self Care concept ((patient participation [ot] OR ambulatory [ot] OR kiosk [ot] OR kiosks [ot] OR self-monitor* [ot] OR self-measure* [ot] OR self-care* [ot] OR self-report* [ot] OR telemonitor* [ot] OR tele-monitor* [ot] OR home monitor* [ot] OR telehealth [ot] OR tele-health [ot] OR telemonitor* [ot] OR tele- monitor* [ot] OR telemedicine [ot] OR patient-directed [tiab] OR “patient directed” [tiab]
    [Show full text]
  • Multimedia Appendix 1. Search Strategy Developed for Medline Via Ovid to Identify Existing Systematics Review. Concept 1: BP
    Multimedia Appendix 1. Search strategy developed for Medline via Ovid to identify existing systematics review. Concept 1: BP lowering regimens 1 exp antihypertensive agents/ 2 (antihypertensive$ adj (agent$ or drug)).tw. 3 exp thiazides/ 4 (chlorothiazide or benzothiadiazine or bendroflumethiazide or cyclopenthiazide or metolazone or xipamide or hydrochlorothiazide or hydroflumethiazide or methyclothiazide or polythiazide or trichlormethiazide or thiazide?).tw. 5 (chlorthalidone or chlortalidone or phthalamudine or chlorphthalidolone or oxodolin or thalitone or hygroton or indapamide or metindamide).tw. 6 ((loop or ceiling) adj diuretic?).tw. 7 (bumetanide or furosemide or torasemide).tw. 8 exp sodium potassium chloride symporter inhibitors/ 9 (eplerenone or amiloride or spironolactone or triamterene).tw. 10 or/1-9 11 exp angiotensin-converting enzyme inhibitors/ 12 ((angiotensin$ or kininase ii or dipeptidyl$) adj3 (convert$ or enzyme or inhibit$ or recept$)).tw. 13 (ace adj3 inhibit$).tw. 14 acei.tw. 15 exp enalapril/ 16 (alacepril or altiopril or benazepril or captopril or ceronapril or cilazapril or delapril or enalapril or fosinopril or idapril or imidapril or lisinopril or moexipril or moveltipril or pentopril or perindopril or quinapril or ramipril or spirapril or temocapril or trandolapril or zofenopril or teprotide).tw. 17 or/11-16 18 exp Angiotensin II Type 1 Receptor Blockers/ 19 (angiotensin$ adj4 receptor$ adj3 (antagon$ or block$)).tw. 20 exp losartan/ 21 (KT3-671 or candesartan or eprosartan or irbesartan or losartan or
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Lubbock EMS MCI Plan
    UMC EMS Emergency Operations Plan And Appendices As of January 2, 2014 © 2014 UMC EMS Version 2014.01 This Page Intentionally Left Blank January 2, 2014 Page 2 TABLE OF CONTENTS Introduction . 4 Levels of Disaster Activation IMS Incident . 5 EMS Command Incident . 5 MCI: Initial Response and Notification . 6 Detection . 6 National Incident Management System (NIMS) . 7 Scene Security and Safety . 7 Assess Hazards . 7 Support . 7 Triage and Treatment . 7 Evacuation . 7 Recovery . 7 Command and Control . 8 Documentation . 9 Personnel Responsibilities . 9 Appendix A – D-I-S-A-S-T-E-R Paradigm . 10 Appendix B – Command and Control Positions . 13 EMS Command . 14 EMS Operations or EMS Branch Director . 15 Triage Group Supervisor . 16 Staging Area Manager . 17 Treatment Group Supervisor . 18 Transport Group Supervisor . 19 Support Group Supervisor . 20 Medical Unit Leader . 21 Appendix C – Flowcharts . 22 Appendix D – Initial Action Checklist . 27 Appendix E – Triage . 28 START . 29 Four Category System . 30 M.A.S.S. 31 JumpSTART . 32 Appendix F – MCI Fatality Management . 33 Appendix G – Hazardous Material Response . 34 Appendix H – Weapons of Mass Destruction . 37 Appendix I – Transport Guidelines . 40 Appendix J – Communications Center Checklist and Phone List. 41 Appendix K – Rehab Protocol . 48 Appendix L – Organized Citizens Response . 50 Appendix M – Forms . 51 January 2, 2014 Page 3 UMC EMS MCI PLAN Introduction UMC EMS, as a member of South Plains Emergency Medical Services, utilizes and supports the regional mass casualty plan. This document is a synopsis of that plan and specific procedures for UMC EMS. It is to be used as a guide during an actual event.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]